Zepbound vs Mounjaro for type 2 diabetes 2026: same drug, different labels

TLDR. Zepbound and Mounjaro are the same molecule: tirzepatide. Eli Lilly markets them under two labels because the FDA approves them for different indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for obesity, obstructive sleep apnea with obesity, and heart failure with preserved ejection fraction with obesity. Commercial insurance covers Mounjaro for T2D on most plans. Zepbound coverage for weight loss is patchier. The clinical effect is identical at the same dose. The right ask is the one that fits the patient's coverage and qualifying indication.

Eli Lilly's tirzepatide is sold under two brand names: Mounjaro for type 2 diabetes, Zepbound for obesity and related indications. The molecule is identical. The pen device for the injectable is identical. The titration schedule is identical. The clinical effect at any given dose is identical.

What differs is everything around the molecule. The FDA label is the central reason patients run into different doors when they ask for one versus the other. A type 2 diabetes patient who walks into an endocrinologist's office and asks for Mounjaro hits a smoother coverage path than the same patient asking for Zepbound. A patient with obesity but no diabetes asking for Mounjaro hits a wall.

This post walks through the actual differences, the insurance dynamics, the cash-pay differences, and the clinical case for asking for one versus the other.

What the FDA labels actually say

Mounjaro was approved by the FDA in May 2022 for adults with type 2 diabetes, as an adjunct to diet and exercise to improve glycemic control. The label specifies use in T2D and explicitly states Mounjaro is not for type 1 diabetes or for weight management without T2D.

Zepbound received its first FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. In December 2024, the FDA expanded Zepbound's label to include moderate-to-severe obstructive sleep apnea with obesity (on the back of the SURMOUNT-OSA trial) and heart failure with preserved ejection fraction with obesity (on the back of the SUMMIT trial).

The label distinction is what insurance plans, prior authorization workflows, and Medicare coverage actually attach to. A formulary covers a drug for a specific indication. Mounjaro's indication is T2D. Zepbound's are obesity, OSA, and HFpEF.

The same molecule, the same trials

Tirzepatide is a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist. It binds both the GLP-1 receptor (the same target as semaglutide) and the GIP receptor (a second incretin pathway). The dual mechanism is the likely explanation for tirzepatide's superior efficacy on weight loss and A1C reduction compared to single-agonist GLP-1s.

The SURPASS trial program tested tirzepatide in type 2 diabetes. SURPASS-2 directly compared tirzepatide to semaglutide 1 mg in 1,879 adults with T2D inadequately controlled on metformin. At 40 weeks, A1C reduction was 1.86 percentage points on semaglutide 1 mg and 2.30 points on tirzepatide 15 mg (Frias et al, NEJM 2021). Body weight reduction was 5.7 kg on semaglutide and 11.2 kg on tirzepatide 15 mg.

The SURMOUNT trial program tested tirzepatide in obesity. SURMOUNT-1 showed 20.9 percent mean body weight reduction at 72 weeks on tirzepatide 15 mg in adults with obesity without diabetes (Jastreboff et al, NEJM 2022). SURMOUNT-2 showed 14.7 percent mean reduction in adults with obesity and T2D.

The trials used the same molecule across the same dose range. Mounjaro is the T2D-labeled product of the SURPASS evidence. Zepbound is the obesity-labeled product of the SURMOUNT evidence. The clinical separation is real at the label level. It is not real at the molecule level.

The insurance dynamics

This is where the choice between Mounjaro and Zepbound becomes the patient's real question.

Mounjaro for T2D is widely covered. Commercial plans cover Mounjaro on roughly 85 percent of formularies, often on tier 2 or tier 3 with a prior authorization that requires documented T2D (A1C of 6.5 or higher, prior diabetes diagnosis, or current diabetes medication). Medicare Part D covers Mounjaro for T2D on essentially all plans with formulary listing. Medicaid coverage varies by state but most state Medicaid programs cover Mounjaro for T2D with a PA.

Zepbound for obesity is patchily covered. Commercial coverage runs roughly 45 to 55 percent of plans, with the rate dropping each year as employer plans drop obesity-drug coverage to manage premium costs. Plans that cover Zepbound usually require a BMI threshold (30, sometimes 35), failed diet attempts, and prior authorization. Medicare does not cover Zepbound for obesity by statute (Medicare Part D is barred from covering AOMs). Medicare does cover Zepbound for OSA with obesity and HFpEF with obesity, the two newer indications. Medicaid coverage for Zepbound for obesity exists in roughly 18 states; coverage for OSA and HFpEF is broader.

The insurance dynamic creates a real arbitrage. A patient with T2D and obesity who asks for Mounjaro gets covered. The same patient asking for Zepbound often does not, even though the molecule is the same.

When to ask for which

The clean rules:

• Type 2 diabetes, no obesity indication needed: Mounjaro. Coverage is broad, PA is routine, the molecule does the job.
• Type 2 diabetes plus obesity, prefer one prescription: Mounjaro. Most plans cover Mounjaro for the T2D indication; weight loss is a documented secondary effect. The prescriber should write for T2D primary.
• Obesity without T2D, commercial insurance covers Zepbound: Zepbound. Use the labeled product.
• Obesity without T2D, commercial insurance excludes obesity drugs: Zepbound through LillyDirect cash-pay vials at $349 to $499, or Zepbound through a telehealth program that bundles. Cash-pay vials are the cheapest non-compounded route.
• Moderate-to-severe OSA with obesity: Zepbound. The SURMOUNT-OSA indication is real, the Medicare coverage is real, the commercial coverage is broader than the obesity-only path.
• HFpEF with obesity: Zepbound. The SUMMIT indication and Medicare coverage apply.
• Cash-pay, T2D, no insurance: Pursue insurance instead. Cash-pay Mounjaro at $1,069 per month at retail is not a sustainable path for most patients. A medically necessary T2D diagnosis is usually covered eventually if the patient sticks with it.

The cash-pay difference

The cash-pay paths diverge sharply.

Mounjaro cash-pay is rough. Retail pharmacy quotes typically run $1,069 to $1,200 per month. Eli Lilly does not currently operate a direct-to-patient cash channel for Mounjaro analogous to LillyDirect for Zepbound. Mounjaro patients without insurance face the worst cash-pay path of any major GLP-1.

Zepbound cash-pay is reasonable. LillyDirect sells single-dose Zepbound vials directly to patients at $349 per month for 2.5 mg and 5 mg starter doses and $499 per month for 7.5 mg and higher maintenance doses. The vial form is slightly different from the auto-injector pen but contains the same tirzepatide solution. Patient draws and injects with a separate syringe.

The result: a cash-pay obesity patient can get tirzepatide for $349 to $499 through Zepbound vials, while a cash-pay T2D patient gets the same molecule under a different label at $1,069 to $1,200. The label, not the chemistry, drives the price spread.

Patients with T2D and no insurance who can document a qualifying weight-related comorbidity can sometimes pivot to Zepbound through a telehealth program, using the obesity indication. This is a workaround, not a clinical recommendation, but the financial math is real.

SURPASS trial data in detail

For T2D patients evaluating tirzepatide, the SURPASS program is the relevant evidence base:

• SURPASS-1 (monotherapy): tirzepatide 5/10/15 mg reduced A1C by 1.87/1.89/2.07 percentage points at 40 weeks in T2D patients not on a background therapy.
• SURPASS-2 (vs semaglutide 1 mg): tirzepatide outperformed semaglutide 1 mg by 0.15 to 0.45 A1C points across doses, with substantially larger weight loss.
• SURPASS-3 (vs insulin degludec): tirzepatide reduced A1C and body weight; insulin degludec increased body weight.
• SURPASS-4 (high CV risk): tirzepatide reduced A1C by 2.41 percentage points at 15 mg, with a nominal but underpowered CV signal.
• SURPASS-5 (added to basal insulin): tirzepatide reduced A1C by 2.11 percentage points at 15 mg.
• SURPASS-CVOT (cardiovascular outcomes): underway, expected to report in late 2026 or 2027. Will determine whether tirzepatide formally matches semaglutide on CV event reduction in T2D.

The SURPASS evidence is the cleanest A1C-reduction evidence for any GLP-1 class drug. It is also the evidence base that the FDA used to approve Mounjaro for T2D. A T2D patient asking for Mounjaro is asking for a drug supported by five completed phase 3 trials in the specific indication being treated.

When the SURPASS-CVOT readout matters

Cardiologists who treat T2D with cardiovascular comorbidity currently default to semaglutide (Ozempic) on the strength of the SUSTAIN-6 and SELECT cardiovascular outcomes data. Mounjaro lacks completed cardiovascular outcomes data in T2D. The SURPASS-CVOT trial is testing whether tirzepatide reduces major adverse cardiovascular events in T2D patients with elevated cardiovascular risk, with results expected in late 2026 or 2027.

If SURPASS-CVOT reads positive (likely, given the mechanistic similarity to semaglutide and the SURPASS-4 CV signal), Mounjaro will gain the same cardiovascular indication as Ozempic. For now, a T2D patient with established CVD has a clinical case for semaglutide rather than tirzepatide; for T2D patients without established CVD, tirzepatide's A1C and weight advantages dominate.

The prescriber preference dimension

Endocrinologists who started prescribing tirzepatide in 2022 know it as Mounjaro and tend to prescribe it for T2D out of habit, even when the patient's primary concern is weight. Obesity-medicine prescribers know it as Zepbound and tend to prescribe Zepbound even when the patient also has T2D. The label preference often follows the prescriber's specialty.

This matters because the prescriber's choice of label determines the prior authorization pathway. A T2D patient whose endocrinologist writes for Mounjaro gets a smoother PA than the same patient whose obesity-medicine prescriber writes for Zepbound. Patients with both indications should ask the prescriber to write for the indication with the cleaner coverage path on the patient's specific plan.

What this means in practice

For most patients with T2D in 2026, the right ask is Mounjaro. Coverage is broad. Cash-pay is bad but most T2D patients have insurance access. The molecule is the strongest GLP-1 evidence base in the diabetes indication.

For most patients with obesity without T2D in 2026, the right ask is Zepbound. Coverage is patchier but improving. Cash-pay through LillyDirect vials at $349 to $499 is the cheapest non-compounded branded path. The molecule is identical.

For patients with both T2D and obesity, the right ask is Mounjaro through the T2D indication for coverage, with weight loss as the documented secondary outcome. The molecule does both jobs at the same dose.

Frequently asked questions

Is Zepbound the same as Mounjaro?

The active molecule is identical: tirzepatide. The pen device, the dose range, the titration schedule, and the clinical effect at the same dose are all the same. The difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for obesity and the obesity-related indications of OSA and HFpEF. Insurance coverage, prior authorization workflow, and cash-pay pricing follow the label, not the molecule.

Can my doctor write Mounjaro for weight loss?

The FDA label for Mounjaro is type 2 diabetes only. A prescriber can legally write Mounjaro off-label for weight loss, and many did during 2022 and 2023 when Zepbound did not yet exist. Most insurance plans will not cover Mounjaro for off-label weight loss; the patient pays cash. If the patient has obesity but no T2D, Zepbound is the labeled product and the path with any chance of insurance coverage.

Why does Mounjaro have better insurance coverage than Zepbound?

Two reasons. First, type 2 diabetes has long-standing precedent as an insurance-covered chronic condition; obesity has been treated as a "lifestyle" issue and excluded from many plan formularies despite obesity medicine's recognition as a chronic disease. Second, Medicare statutorily excludes anti-obesity medications from Part D coverage, which sets a precedent that commercial plans often follow for cost reasons. The result: a T2D indication carries broader coverage than an obesity indication for the same molecule.

Is Zepbound cheaper than Mounjaro in cash-pay?

Yes, by a wide margin. Zepbound vials through LillyDirect cost $349 to $499 per month. Mounjaro at retail pharmacy without insurance runs $1,069 to $1,200 per month. Eli Lilly has not launched an equivalent direct-to-patient cash channel for Mounjaro. A T2D patient who can document a weight-related comorbidity can sometimes pivot to Zepbound for the financial relief, but the cleaner path is to pursue insurance coverage for Mounjaro, which most T2D patients can get.

Does Medicare cover Zepbound?

Medicare does not cover Zepbound for obesity (Part D statutory exclusion of AOMs). Medicare does cover Zepbound for moderate-to-severe obstructive sleep apnea with obesity (SURMOUNT-OSA indication, approved December 2024) and heart failure with preserved ejection fraction with obesity (SUMMIT indication, approved December 2024). A Medicare patient with one of those qualifying indications has Zepbound access; a Medicare patient with obesity alone does not.

If SURPASS-CVOT is positive, will I switch from semaglutide to tirzepatide?

That is the open question. A positive SURPASS-CVOT readout would give tirzepatide the cardiovascular event-reduction indication that semaglutide already has from SELECT and SUSTAIN-6. For T2D patients without established CVD, the SURPASS A1C and weight data already favor tirzepatide. For T2D patients with established CVD, the choice has been semaglutide on the strength of the completed CVOT. A positive SURPASS-CVOT readout would close that gap and let prescribers default to tirzepatide more broadly.

Is the SURPASS-2 superiority over semaglutide settled?

For A1C reduction at the head-to-head doses tested (tirzepatide up to 15 mg vs semaglutide 1 mg), yes. For weight loss across the broader dose range, the obesity comparison from SURMOUNT-5 confirmed superiority: tirzepatide 10 to 15 mg produced 20.2 percent body weight reduction vs 13.7 percent for semaglutide 2.4 mg (Aronne et al, NEJM 2025). The molecule comparison favors tirzepatide on the primary efficacy endpoints, with overlapping side-effect profiles.

Citations

• Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM 2021;385:503-515. nejm.org/doi/full/10.1056/NEJMoa2107519
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216. nejm.org/doi/full/10.1056/NEJMoa2206038
• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM 2025;392:2061-2071. nejm.org/doi/full/10.1056/NEJMoa2416394
• Malhotra A, et al. Tirzepatide for Obstructive Sleep Apnea (SURMOUNT-OSA). NEJM 2024;391:1193-1205. nejm.org/doi/full/10.1056/NEJMoa2404881
• Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction (SUMMIT). NEJM 2025;392:427-437. nejm.org/doi/full/10.1056/NEJMoa2410027
• FDA. Mounjaro (tirzepatide) prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2024/215866s016lbl.pdf
• FDA. Zepbound (tirzepatide) prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2024/217806s006lbl.pdf